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Abstract
  . 2q .CaMK-II the type II multifunctional Ca rCaM-dependent protein kinase has been implicated in diverse neuronal
and non-neuronal functions, including cell growth control. CaMKII expression was evaluated in a variety of human tumor
 .cell lines using RT-PCR reverse transcriptase coupled polymerase chain reaction . PCR primers which flanked the
 .CaMK-II variable domain were used so that all possible variants of the four mammalian CaMK-II genes a , b , g and d
could be identified. 8 distinct CaMK-II isozymes were identified from human mammary tumor and neuroblastoma cell
 X.cDNA, each of which represented a variant of b , g or d CaMK-II. They included 2 b isozymes b , b , 4 g isozymese e
 .  .g , g , g , g and 2 d isozymes d , d This is the first report of human b and d CaMK-II sequences.B C G H C E
A panel of human cell types was then screened for these CaMK-II isozymes. As expected, cerebral cortex predominately
expressed a , b and d CaMK-II. In contrast, tumor cells, including those of neuronal origin, expressed an entirelyA
different spectrum of CaMK-II isozymes than adult neuronal tissue. Tumor cells of diverse tissue origin uniformly lacked a
CaMK-II and expressed 1–2 b isozymes, at least 3 g isozymes and 1–2 d isozymes. When compared to undifferentiated
fibroblasts, b , b X, g and g were preferentially expressed in tumor cells. CaMK-II immunoblots also indicated thate e G H
neuroblastoma and mammary tumor cells express isozymes of CaMK-II not present in their non-transformed cell or tissue
counterpart. The identification of these new, potential tumor-specific CaMK-II variants supports previous indications that
CaMK-II plays a role in growth control. In addition, these results provide insight into both splice variant switching and
variable domain structural similarities among all CaMK-II isozymes.
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1. Introduction
Mammalian cell growth is dependent upon Ca2q
 .operating through calmodulin CaM during the G1
w xphase of the cell cycle 1–3 . Transient elevations of
 .Abbreviations: CaM, calmodulin; CaMK-II, type II multi-
functional Ca2qrCaM-dependent protein kinase; RT-PCR, re-
verse transcriptase coupled polymerase chain reaction
)  .Corresponding author. Fax: q1 804 8288079.
Ca2q occur in response to growth factors and CaM
w xpeaks in mass during G1 1–3 . The ablation or
w xinhibition of CaM arrests cells during G1 4–6 and
cellular transformation can lead to elevated levels of
w xCaM 7 . CaM has a number of potential targets
through which it could act to channel Ca2q signals
into the growth regulatory machinery, including the
w xfamily of CaM-dependent protein kinases 8 . Of the
6 different CaM kinases, which include CaMK I
through IV, myosin light chain kinase and phosphory-
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lase kinase, only CaMK-I and CaMK-II are uni-
w xformly expressed in proliferative cells 8,9 . CaMK-IV
is regulated by other kinases and has been implicated
in transcriptional regulation, but is specific to neu-
w xronal and reproductive cells 10,11 . In mammalian
cells, CaMK-II is encoded by four known genes: a ,
b , g and d , to give rise to over a dozen CaMK-II
subtypes, presumably through alternative splicing
w x12–14 .
  . 2qCaMK-II the type II multifunctional Ca rCaM
.kinase was originally discovered as a major protein
in differentiated neuronal tissue where it was impli-
cated in long-term potentiation and neurotransmitter
w xrelease 15,16 . CaMK-II has since been discovered
w xin yeast, mold, fruit flies and humans 17–19 . It has
been linked to the regulation of carbohydrate
metabolism, membrane fusion and the cell cycle in
w xnon-neuronal cells 20–24 . CaMK-II activity and
polypeptides have been found in proliferative cells in
w xculture 23,25 and CaMK-II has been reported to be
activated within 20 sec of growth induction by serum,
w xPDGF, EGF or bradykinin 26,27 . CaMK-II in-
hibitory drugs arrest mammalian cells in G1 and S
w xphase 22,23,28 and block the expression of early
response genes, such as fos, which are necessary for
w xcell growth 11,29 .
CaMK-II isozymes are encoded as single poly-
peptides, each containing a catalytic, a regulatory, a
variable and an association domain with predicted
masses between 54 and 60 kDa. The catalytic domain
has features common to most serinerthreonine pro-
tein kinases. The regulatory domain is the site of
CaM binding and autophosphorylation, through which
CaMK-II can sustain its own activity after a Ca2q
w x 2qsurge 9,30 . The generation of Ca -independent or
autonomous activity in this manner is believed to
comprise the molecular basis for long-term functions
of CaMK-II. The regulatory domain is adjacent to a
region of high variability where most differences
between the four CaMK-II genes and among the
w xsplice variants are located 9 . It is believed that this
region serves in part as an elongated tether between
the catalytic and association domains and is therefore
exposed to other proteins enabling it to associate with
w xsub-cellular organelles or substrates 12,14 . The as-
sociation domain is responsible for the oligomeriza-
tion of CaMK-II, a trait unique to this member of the
CaM kinase family.
Neuronal-specific functions of multifunctional
CaMK-II are believed to be carried out by a and b
CaMK-II, while the widespread distribution of g and
d suggests that they may be involved in functions
w xcommon to all cells 31 . Non-neuronal functions of
b CaMK-II, however, are suggested by the embry-
onic lethality of a transgenic mouse strain in which b
w xCaMK-II is disrupted 32 and the identification of a
non-neuronal isozyme of b CaMK-II in rat pancre-
w xatic cells 33 . Tissue-specific expression of CaMK-II
genes and of their splice variants has been reported
w xfor g CaMKII’s 34,35 . d CaMK-II isozymes are
expressed in both neuronal and non-neuronal cells,
with two domains of variability leading to over 6
w xdifferent splice variants 13,36,37 .
Although CaMK-II has been implicated in mam-
malian growth control during G1, it is not known
which CaMK-II isozymes are expressed in prolifera-
tive cells and therefore which ones might be involved
in regulating growth. A comprehensive analysis of
CaMK-II isozyme expression in non-neuronal, undif-
ferentiated cells has been lacking. In this study, the
entire spectrum of CaMK-II isozymes expressed in a
panel of human tumor cell lines was characterized by
using PCR primers which were conserved amongst
all CaMK-II’s. The partial cDNA sequence of 6
human b , g and d CaMK-II splice variants is re-
ported, some of which are novel and may be prefer-
entially expressed in tumor cells.
2. Materials and methods
2.1. Cell lines and culture
The following cell lines were used to prepare RNA
and are indicated with tumor type of origin and
 .American Type Culture Collection ATCC number.
Human breast cancer cell lines included: MCF7:
 .breast adenocarcinoma HTB 22 ; ZR 75-1: ductal
 .carcinoma CRL 1500 ; DU4475: metastatic cuta-
 .neous nodule HTB 123 ; MDA-MB361: adeno-
 .carcinoma HTB 27 and SK-BR-3: adenocarcinoma
 .HTB 30 . Other cell lines included CCRF-CEM:
 .lymphoblastic leukemia CCL 119 ; HT-29: colon
 .adenocarcinoma HTB 38 ; MCF10A: mammary ep-
 .ithelial cells CRL 10317 and WI-38 embryonic lung
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 .fibroblasts CCL75 . NIH 3T3 mouse embryo fibrob-
 .lasts CRL 1658 and the human neuroblastoma LAN5
w xcell line 38 were also used. Cells were cultured on
polystyrene dishes or in suspension in polystyrene
flasks in DMEM or RPMI-1640 BioWhitaker, Walk-
. ersville, MD and 10% fetal bovine serum GIBCO-
.BRL, Bethesda, MD , supplemented with
penicillinrstreptomycin in a 5% CO humidified2
chamber @378C.
2.2. RT-PCR
Total RNA was isolated from exponentially grow-
w x qing cells as described 39 . Poly A RNA was iso-
lated directly from cell lysates using oligo-dT cellu-
 .lose Invitrogen, San Diego, CA . First strand cDNA
was prepared from 5 mg total RNA or approx. 50 ng
poly Aq RNA using oligo dT -primer and AMV16
reverse transcriptase Life Technologies, Gaithers-
.burg, MD . Oligo-dT-primed adult human cerebral
cortex and human mammary tissue cDNA were ob-
tained from commercial sources Clontech, Palo Alto,
.CA .
For the primary PCR reactions used to identify
 .  .CaMK-II classes Fig. 2 , 1 ml of cDNA 1–2 ng
w xwas subjected to nested PCR 40,41 . PCR reactions
were conducted in 50 ml containing 1.5 mM MgCl ,2
0.2 mM dNTP, 4 mgrml sense and anti-sense primers
and 0.2 Units Taq polymerase Perkin Elmer Inc.,
.Foster City CA . Primary PCR reactions were con-
ducted for 20 cycles with 1 min at 928C, 1.5 min at
428C and 2 min at 728C. Nested secondary PCR
reactions were conducted with 2 ml of the primary
reaction diluted in 50 ml total volume and cycled 35
times with 1 min at 928C, 1.5 min at 508C and 2 min
at 728C. PCR amplification conditions were opti-
mized for MgCl concentration and hybridization2
temperature using CaMK-II clones and for the mini-
mum cycle number and cDNA concentration neces-
sary to achieve strong bands from brain cDNA, which
was known to express all CaMK-II mRNAs. PCR
primers were designed from the variable domain of
CaMK-II, which is at the C-terminal end of the
CaM-binding domain and where almost all of the
variability exists among isozymes. The sense primer
for the primary PCR reactions was 5X-GGGACA-
CAGTGACACCTGAAGC-3X, corresponding to
amino acids WDTVTPEA residues 238–245 in hu-
.man g CaMK-II and the anti-sense primer wasB
X w x w xw x w x5 -GGTT CrT AGGATG ArG ArG T ArG G-
w x X T ArG TG-3 corresponding to HTTILNP residues
.  .451–457 in g CaMK-II . The secondary nestedB
PCR reaction used the same anti-sense primer with
the following sense primer: 5X-GGTGCCA-
w x w x w x w x XTC CrT T CrG AC CrGrA AC CrT ATGCT-3
corresponding to the amino acid sequence GAILTT-
 302 – 309.ML g CaMK-II . Products were separatedB
on 3% low melting point agarose for 2 h at 80 V and
visualized with ethidium bromide.
To further define isozyme expression in various
 .cell lines Fig. 4 , nested PCR was again used under
the same conditions described above. After the same
Fig. 1. CaMK-II primary structure and PCR primer design. All 4 mammalian CaMK-II genes are composed of catalytic, regulatory,
 .variable and association regions. PCR primers arrows which were common to all CaMK-II’s were used to amplify sequences contained
within the variable and a portion of the association region.
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Fig. 2. CaMK-II variable region amplification and cloning by
RT-PCR from mammary tumor cells. Oligo dT-primed first
strand cDNA from ZR-75-1 mammary tumor cells was subjected
to PCR using the primers designated in Fig. 1. The resulting PCR
 .products lanes 1 and 8: MIX were directly cloned. Clones were
then re-amplified with the same primer set and separated on a 3%
 .agarose gel to reveal 6 size classes I–VI .
PCR primers used in Fig. 2 were used in primary
reactions on first strand cDNA, the following anti-
sense primers for a , b , g and d CaMK-II were used
in the secondary PCR reaction with the ‘GAILT-
TML’ sense primer. For a CaMK-II: 5X-TTGTTTC-
w x XCTCC ArG CTCTTCCC-3 , corresponding to rat a
CAMK-II315– 322: GGKSGGNK; for b CaMK-II: 5X-
TTTGGTGCTGTTTGTCTGGG-3X, corresponding to
human b CaMK-II329 – 335: PQTNSTK; for ge
CaMK-II: 5X-TACCACGTGGTTTGTGGCTC-3X,
corresponding to human g CaMK-II 354 – 360:B
EPQTTVV and for d CaMK-II: 5X-TTTATTGATTT-
TGGACAAAGC-3X, corresponding to human dC
CaMK-II404 – 409: KSNKPI.
2.3. Cloning and sequencing
PCR products were cloned directly into the ‘TrA’
 .cloning vector, pCR-II Invitrogen, San Diego CA .
Plasmid DNA was then purified from isolated clones
w xusing selective isopropanol precipitation 39 . Se-
quencing was conducted in duplicate by SP6 or T7
primed fluorescently tagged dideoxynucleotide termi-
w xnator sequencing reactions 42 for automated se-
 .quencing Applied Biosystems, Foster City, CA .
Consensus sequences from at least 3 separate clones
were used to compile the final sequences reported.
GenBank Accession Numbers are U50358 for b ,e
U50359 for g , U50360 for g , U50361 for d andG H C
U73738 for d .E
2.4. Cytosol preparation
In order to examine both CaMK-II activity and
immunoreactive polypeptides, cytosolic fractions
were prepared from cells harvested by either scraping
or detaching with trypsin-EDTA and rinsing centrifu-
 . gally 2000=g for 5 min with PBS phosphate
.buffered saline containing 5 mM EDTA. Cellular
pellets were dissolved in 3 volumes of homogeniza-
tion buffer, which consisted of 20 mM Hepes, pH
7.4, 2.6 mM EDTA, 20 mM MgCl , 80 mM b-2
glycerol phosphate, 50 mM NaF, 0.1 mM dithio-
threitol, 0.01 mgrml each chymostatin, leupeptin,
aprotinin, pepstatin and soybean trypsin inhibitor
 .Sigma, St. Louis MO . Dissolved samples were then
 .sonicated two 5-s bursts on ice , centrifuged at
10 000=g for 15 min at 48C and either assayed
immediately or stored at y708C. Lysates prepared by
sonication solubilized over 90% of the total CaMK-II
w xas measured by solution assays 23 .
2.5. CaMK-II immunoblots
1–10 mg cytosol was diluted with an equal vol-
w xume of preheated 2= sample buffer 43 , followed
by boiling for 3 min. Protein concentrations were
 .determined by BCA assay Pierce, Rockford IL in
triplicate. Discontinuous SDS gels were prepared with
7% polyacrylamide. Proteins were transferred to
nitrocellulose and nitrocellulose was blocked by a 1 h
 .incubation with 5% bovine serum albumin BSA ,
2% normal goat serum in Tris-buffered saline con-
 .taining 0.05% Tween-20 TBST . The primary anti-
body incubation was overnight at room temperature
with a rabbit polyclonal anti-CaMK-II antibody UBI,
.Lake Placid, NY diluted to 1 mgrml in TBSTr1%
BSA. This antibody was prepared against an N-termi-
nal and C-terminal peptide immunogen common to
all known CaMK-II isozymes. Blots were rinsed 3
times with TBST and then incubated for 1 h at room
temperature with 0.25 mgrml biotinylated goat anti-
 .mouse IgG KPL, Gaithersburg, MD . Blots were
rinsed 3 times with TBST and then incubated for 1 h
at room temperature with 2.5 mgrml streptavidin-
alkaline phosphatase Molecular Probes, Eugene,
.OR . After 3 rinses in TBST, blots were rinsed once
in 0.1 M NaCl, 50 mM MgCl , 30 mM Tris, pH 9.22
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and then developed with 50 mgrml nitro blue tetra-
zolium and 50 mgrml 5-Br, 4-Cl indolyl phosphate
in this buffer.
3. Results
3.1. Human tumor cells express as many as 8 differ-
ent isozymes of CaMK-II
CaMK-II activity has previously been detected in
w xnon-neuronal proliferative cells 23,25 and has been
w ximplicated in the regulation of growth control 22,23 .
In order to further investigate the role of CaMK-II in
growth control, this study used a comprehensive
strategy to identify all expressed CaMK-II isozymes
in human tumor and in other non-transformed cell
lines. Since isozyme complexity is believed to be
accomplished by alternative splicing in each of the
 . w xfour mammalian a , b , g and d CaMK-II genes 9
in a domain which spans the variable domain and a
portion of the association domain, PCR primers were
chosen which bracketed this entire region and were
 .common to all CaMK-II’s Section 2, Fig. 1 . Nested
sets of PCR primers were used to amplify sequences
from oligo dT-primed cDNA. PCR amplification con-
ditions were optimized using brain cDNA see Sec-
.tion 2 . When RNA from the human mammary tumor
cell line, ZR-75-1, was used as the template for
cDNA synthesis and PCR, a mixture of bands be-
 .tween 350 and 550 bp Fig. 2, lanes 1 and 8: Mix
was observed. This entire mixture was directly cloned,
without fractionation and 85 positive clones were
then evaluated. Upon amplification with the same
primer set, each clone exhibited one of the bands
from the PCR mixture in the size range of 350 to 550
bp. A representative clone from each one of the 6
 .  .size classes I–VI is shown lanes 2–7 . Approx.
70% of these clones were in class VI, reflecting the
predominance of this size band in the initial PCR
product mixture. All other classes were approxi-
mately equally represented.
Two to five clones representing each cDNA class
 .were sequenced Fig. 3 . Sequencing confirmed that
each of the 6 separate size classes shown in Fig. 2
represented distinct CaMKII cDNA types. Of the 6
cDNA classes, I,II,III and V were most similar to
known g CaMK-II isozymes, IV was most like b
CaMK-II and VI like d CaMK-II. Classes II and V
were identical to human CaMK-II g and g , respec-B C
w xtively, at the nucleotide level 34 . Two additional
CaMK-II isozymes were cloned in a similar way
from cDNA from the LAN5 neuroblastoma cell line.
These two additional clones were most like a b
CaMK-II and a d CaMK-II, respectively. Fig. 3
Fig. 3. Predicted amino acid sequence of human CaMK-II b , g , g and d . Clones representing all 6 size classes from ZR-75-1E G H C
 .  .cDNA Fig. 2 were sequenced. Classes II and V represented known human CaMK-II sequences g and g CaMK-II . The other 4B C
classes represent novel human sequences. Two additional novel human cDNA’s were cloned from LAN5 neuroblastoma cells. The
 Xpredicted amino acid sequences of the 6 unpublished human CaMK-II’s b , b , g , g d , and d are shown aligned to each other.e e G H C E
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shows the predicted amino acid sequences across the
variable domain of the 6 novel human CaMK-II
isozymes reported here. There are two variants of g
 .CaMK-II, g and g , two variants of b CaMK-II,G H
 X. b and b , and two variants of d CaMK-II, de e C
. w xand d identified in this study 13,35,37 .E
CaMK-II b has a structure which would be pre-e
dicted for a splice variant lacking two exons, when
w xcompared to the rodent b CaMK-II gene 32 . This
isozyme has been called b since it was originallye
discovered in embryonic rat brain, along with CaMK-
X w xII b 44 . Where the sequences align, human be
CaMK-II was identical to the corresponding sequence
in rodent b CaMK-II in 91% of 423 nucleotides and
w xin 96% of 141 amino acids 32 excluding the two
gaps. The LAN5 b X clone lacks an additional exone
when compared to b . None of the b clones detectede
here contained the proline-rich domain found in
w xCaMK-II b 33 . There is no evidence for b3 3
CaMK-II in ZR-75-1 or LAN5 cells as it would have
 .a variable domain PCR product size 675 bp outside
 .of the range observed Fig. 2 . This is the first report
of human b CaMK-II sequences and the second
w xexample of non-neuronal b CaMK-II 33 .
Both g and g CaMK-II contain inserts whichG H
are missing from previously described human non-
 .neuronal g CaMK-II’s g and g , but are other-B C
w xwise identical in nucleotide sequence 34 . These
isozymes are distinct from g and g CaMK-II,D E
isozymes recently identified in human biliary epithe-
w xlial cells 35 .
d CaMK-II was the most predominant cloneC
found in this screen. Also known as d , this cDNA2
was identical to rodent CaMK-II in 93% of the
w xnucleotides and in 98% of the amino acids 13,37 .
An additional CaMK-II d isozyme, d is also re-E
ported here. The partial cDNA encoding this isozyme
was cloned from the neuroblastoma cell line, LAN5.
d represents a novel variant of d CaMK-II andE
contains an additional domain when compared to dC
CaMK-II. These are also the first reports of any
human d sequences.
3.2. Human tumor cells express a unique pallern of
CaMK-II isozymes
Based in part on the human sequences reported
here, four additional PCR primer sets were prepared
in order to screen cDNA’s from a wide variety of
different human cell types for the expression of
CaMK-II variants from the four mammalian CaMK-II
genes. These additional primers were also nested
within the first primer set used in Fig. 1 see Section
. 2 and were specific for each of the 4 a , b , g and
.d mammalian CaMK-II genes. Approximately
equivalent amounts of cDNA from neuronal tissue,
tumor cells, embryonic fibroblasts and non-malignant
mammary epithelial cells and tissue were examined
with each of these 4 primer sets under identical
 .conditions of amplification Fig. 4 . Although this
study was not strictly quantitative PCR, these results
indicate that a completely different spectrum of
CaMK-II cDNA’s was found in adult neuronal tissue
 .lane 2 than in tumor or ‘normal’ cells, including
 .those of neuronal origin lanes 3–11 .
 .Human cerebral cortex lane 2 and rat cerebral
 .cortex cDNA not shown expressed identical spectra
of CaMK-II isozymes. a CaMK-II expression is
indicated by co-migration with a rodent a CaMK-II
 .cDNA standard lane 12 . b CaMK-II was identified
by a principal band at 195 bp from cerebral cortex, as
expected for neuronal b CaMK-II. A weak band at
110 bp was also observed which co-migrated with
that amplified from the b CaMK-II cDNA standarde
 .lane 12 . Multiple g CaMK-II variants were ex-
 .pressed in neuronal cells. g CaMK-II 205 bp wasA
weakly amplified from rat and human neuronal
cDNA. The 185 bp band co-migrated with the stan-
 .dard for g lane 12 and the 145 bp band co-migratedB
 .with the g rg CaMK-II standard lane 13 . gG H C
 .CaMK-II yields a band at 115 bp lane 14 , but this
was absent from cerebral cortex. The major bands at
250 and 170 bp are most likely neuronal b and dA
CaMK-II, respectively, which are the principal repre-
sentatives of their respective genes and which share
sequences with the g primer pair. Due to the com-
plexity in g CaMK-II variants, as revealed by this
study, not all g CaMK-II variants can be distin-
guished by the PCR primers used here. Rather, gel
analysis of PCR products defines g CaMK-II sub-
 .classes as indicated in Fig. 4. d CaMK-II 420 bpA
is the principal d CaMK-II in neuronal tissue and as
with b CaMK-II, there are trace amounts of the
truncated variants d and d CaMK-II at 380 andE C
320 bp, respectively.
a CaMK-II was never detected in any other cell
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 .type examined lanes 3–11 , including those derived
 .from a neuronal tumor lane 3 . Likewise, the neu-
ronal b CaMK-II was never observed in cells other
 X.  .than adult brain. b or b CaMK-II 110 bp wase e
the only b CaMK-II seen in these cells and its
expression was variable. b rb X was observed ine e
 .neuroblastoma lane 3 and mammary tumor cells
 .lane 7 , but was absent from all other tumor cell
 .lines, including small cell lung carcinoma lane 4 ,
 .  .colon carcinoma lane 5 and leukemic lane 6 cells.
 .cDNA from non-malignant mammary tissue lane 8
or a non-transformed breast epithelial cell line,
 .MCF10 A lane 9 , also contained this band, but it
was consistently less intense when compared under
identical amplification conditions to the ZR-75-1 cell
line. Other mammary tumor cells were screened un-
der identical conditions and expressed similar levels
 .of b CaMK-II to ZR-75-1 cells data not shown .e
 .  .Embryonic human lane 10 or rodent lane 11 fi-
broblasts also contained b CaMK-II. These PCRe
w xprimers cannot distinguish b CaMK-II 33 from b3 e
or b X CaMK-II, since they share sequences in thise
region. However, b CaMK-II was not detected in3
ZR-75-1 or LAN5 tumor cells, since a band with the
 .predicted size 675 bp for the b variable domain3
was not observed with the common variable domain
 .primer set Fig. 2 .
g and g CaMK-II 185 and 115 bp, respec-B C
.tively were consistently seen in every nonneuronal
cell line examined, in contrast to the absence of a
CaMK-II and the variable expression of b CaMK-II.
Since these comparative studies were done simultane-
Fig. 4. RT-PCR analysis of a , b , g and d CaMK-II in human cells and tissues. Oligo dT-primed cDNA from adult human cerebral
 .  .  .  .  .cortex 2 , LAN5 neuroblastoma 3 , H146 small cell lung carcinoma 4 , HT29 colon carcinoma 5 , CEM leukemic 6 ; ZR751
 .  .  .  .mammary tumor cells 7 , normal mammary tissue 8 , non-malignant mammary epithelial cells 9 , WI-38 human fibroblasts 10 and
 .rodent NIH 3T3 cells 11 was subjected to nested PCR as described in Section 2. a , b , g , and d were amplified with theirE B C
respective primer sets and are shown in lane 12. Lanes 13 and 14 in the g CaMK-II panel are g and g , respectively. Expected PCRG C
products from all known CaMK-II variants are indicated.
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Fig. 5. Identification of CaMK-II polypeptides in human tumor
 .cells. 4 mg of cytosol from rat brain Ctx and 8 mg from each of
the indicated cells was separated by SDS-PAGE, transferred to
nitrocellulose and probed with a pan-specific polyclonal antibody
 .against CaMK-II. Samples included rat brain cortex: Ctx ; neu-
 .roblastoma LAN5 ; immortalized mammary epithelial cell line
 .  .MCF10 A and mammary adenocarcinoma MCF7 . Relative
masses are indicated for a , b , g and d . Large arrows indicateB C
bands which are expressed in tumor cells, but absent from
comparable non-transformed tissue or cells.
ously from the same source of cDNA, g and gB C
CaMK-II serve as excellent internal controls for the
variability in the expression of other genes. As previ-
w xously shown by RNase protection 34 and by the
relative level of amplification of g variants shown
here, g is the predominant g splice variant inB
nonneuronal cells. Tumor cells preferentially ex-
pressed bands which co-migrated with the gG
 .CaMK-II standard lane 13 , when compared to non-
malignant fibroblasts.
d CaMK-II was also consistently seen in everyC
non-neuronal cell line examined, regardless of malig-
nant status. Although neuroblastoma cells expressed
both d and d CaMK-II, not a single malignant orC E
non-neuronal proliferative cell line expressed dA
CaMK-II, the primary d CaMK-II in rodent and
human cerebral cortex.
CaMK-II immunoblots were also conducted on
 .selected tissues and cell lines Fig. 5 in order to
qualitatively corroborate the RT-PCR findings at the
protein level. Soluble lysates were prepared from rat
cerebral cortex and from the human cell lines LAN5
 . neuroblastoma , MCF10A mammary epithelial cell
.  .line and MCF7 mammary adenocarcinoma . Fresh
rat cerebral cortex was used since it yields an identi-
cal spectrum of CaMK-II isozymes to human cerebral
cortex when compared by RT-PCR. Results of this
experiment indicated that transformed cells expressed
CaMK-II proteins not present in their non-trans-
formed counterparts. For example, cerebral cortex
 .Ctx contains major CaMK-II polypeptides of M 50r
and 60 kDa and less intense bands at 51 and 58 kDa,
as expected. The 50 kDa band is believed to represent
a CaMK-II, the 60 kDa band represents b CaMK-II
w xwhile d CaMK-II has a M of 59 kDa 13,45 . InA r
contrast, LAN5 cells lack the 50 and 60 kDa a and
b CaMK-II bands; they are replaced by reactive
 .proteins at 61r62 kDa doublet , 57 kDa, 54 kDa
 .arrow; strongest reactivity and 51 kDa. The band at
approx. 48 kDa is unidentified. From RT-PCR, LAN5
cells express b or b X at least three g isozymes ande e
 .the two d isozymes, d and d Fig. 4, lane 3 . TheC E
62 kDa band co-migrates with that expected for
CaMK-II g and the 61 kDa band with that predictedB
for CaMK-II g . Rat embryonic brain b and b XG e e
CaMK-II have M of 58 and 56 kDa, respectivelyr
w x w x44 . d CaMK-II has a predicted M of 51 kDa 13C r
and d CaMK-II an M of 53 kDa. Although it isE r
unclear which isozyme the major immunoreative 54
 .kDa CaMK-II arrow represents, it is clear that this
and other bands are absent from adult brain. Like-
wise, although both MCF7 and MCF10 A cells ex-
press the 51 and 62 kDa CaMK-II proteins, there are
CaMK-II proteins in MCF7 cells which are not pre-
sent in their non-transformed counterpart, MCF10 A
 .lanes 3 and 4 . The spectrum of CaMK-II proteins,
like mRNA’s, is similar amongst the human tumor
cell lines, LAN5 and MCF7 and indicate that while
d and g are uniformly expressed in all prolifera-C B
tive cells, b rb X, g and g are preferentially ex-e e G H
pressed in tumor cells.
4. Discussion
This study has identified at least 8 separate CaMK-
II isozymes which are expressed in human cell lines
derived from a wide variety of tumors, but which are
absent from adult neuronal tissue. The 8 tumor cell
CaMK-II isozymes described here are products of the
 X. b CaMK-II gene b , b , the g CaMK-II gene g ,e e B
.  .g , g and g and the d CaMK-II gene d , d .C G H C E
 .Three of these isozymes g , g and d have notG H E
previously been reported. Although only b CaMK-II
isozymes have been confirmed as splice variants by
comparison to the rodent b CaMK-II gene, it is
widely believed that variants of all four CaMK-II
w xgenes 13,14,18,19,33,36 are achieved through alter-
native splicing in the variable domain. The total
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Fig. 6. CaMK-II variable region domain structure. The variable domain structure of all known CaMK-II cDNA’s is represented
schematically based on the concept that the 4 genes are related. Sequences were obtained from both rodent and human CaMK-II’s.
Variable domains I through X are based on the b CaMK-II exon structure as well as on cDNA’s which contain or omit one of these
 .domains upper panel . Domains II and VII are darkened to indicate their proposed role as a conserved tether in all isozymes. All known
CaMK-II isozymes are indicated schematically by lines which connect domains and are summarized by domain composition lower right
.  .panel . Domain sequence is also indicated in single letter amino acid code lower left panel .
( )R.M. Tombes, G.W. KrystalrBiochimica et Biophysica Acta 1355 1997 281–292290
number of mammalian CaMK-II isozymes achieved
through variations in this domain is now at least 20,
including 2 a , 5 b , 8 g and 5 d . Additional d
CaMK-II isozymes are achieved through variations at
w xthe C-terminus 36 . This is also the first report of
human b and d CaMK-II sequences. It also confirms
recent and new indications that b CaMK-II is not
w xexclusively expressed in the brain 33 .
Although the role of each of these isozymes in cell
function is not yet known, the expression of over 20
CaMK-II isozymes is consistent with the multiple
functions implicated for CaMK-II, including mem-
ory, secretion, metabolism and cell growth control.
The results presented here confirm that CaMK-II
expression is modulated at the level of mRNA splic-
ing. Tumor cell lines, including the neuroblastoma
cell line, LAN5 and the H146 small cell lung carci-
noma cell line, which is of neuroendocrine origin,
lose almost every neuronal-specific CaMKII isozyme,
even though 3 of the 4 CaMK-II genes continue to
express product.
Careful examination of the sequence of all known
CaMK-II isozymes has revealed ten separate domains
 .which are subject to splicing Fig. 6 . Each of these
domains may have a particular function which may
be associated with the cell type in which the
 .isozyme s which contain that domain are expressed.
 .The boundaries of these domains I–X were derived
from the known intron-exon structure of b CaMK-II
w x32 and from cDNA’s whose exon boundaries are
not known, but were predicted from differences be-
tween isozymes. As shown, each of these domains
has similar length and sequence between genes, al-
though some domains are gene-specific. Each known
CaMK-II variant is composed of between 3 and 7 of
these separate domains, presumably achieved through
alternative splicing. The lines connecting these do-
 .mains Fig. 6 represent all known possibilities.
Variations in the domain use among the four
CaMK-II genes occur in a progressively complex
manner suggestive of an evolutionary hierarchy. For
example, in bctween the two ‘tether’ domains, II and
VII, the only optional domain in a CaMK-II is
domain III and in b CaMK-II, domain VI. In con-
trast, g and d CaMK-II optional domains include all
of those between III and VI. In other words, g and d
CaMK-II use a combination of domain options from
a and b CaMK-II. Further options, particular to b ,
g and d CaMK-II on both the N-terminal side of
domain II and the C-terminal side of domain VII,
increase the number of existing and potential gene
products. These observations suggest that a shift in
splicing signals could act similarly upon all CaMK-II
genes to restrict or expand the spectrum of isozymes
expressed in different tissues.
All CaMK-II’s can be described based on the
presence or absence of domains. All 8 of the tumor
cell CaMK-II isozymes identified here and implicated
 .from isozyme-specific PCR Fig. 4 , lack domain I.
In fact, domain I has only been found in neuronal-
specific b and g isozymes; it is missing from every
non-neuronal CaMK-II isozyme identified. It has been
suggested that domain I may influence the binding
w xaffinity for CaM 13 since it resides on the catalytic
 .side of the invariant tether domain II . In b CaMK-II,
the exon just prior to domain I comprises the C-
w xterminal CaM binding domain 32,46 . From struc-
tural analysis, Leu300 and Leu309 are responsible for
interacting with the N- and C-terminal hydrophobic
w x 309binding pockets of CaM 47 . Leu is only 7 amino
acids from this missing domain in b CaMK-II.e
Thr 305 and Thr 306 and Ser 314 are sites of autophos-
phorylation in neuronal CaMK-II known to influence
w xcatalytic activity 30 . It is possible that phosphoryla-
tion or elimination of domain I may influence CaM
binding and therefore catalytic activity.
Domain II represents the invariable ‘tether’ do-
main found in every CaMK-II isozyme. It is thought
to connect the regulatory and variable regions. Do-
main III is found in only 3 cDNA’s and is responsi-
w xble for nuclear targeting 14 . Of the tumor cells
evaluated here, none expressed a putative nuclear
targeted CaMK-II isozyme. CaMK-II has been re-
w xported in the nucleus of proliferative cells 48 and
may contribute to the regulation of gene expression
w x11 , however, none of the 8 CaMK-II isozymes
found in human tumor cells contain this nuclear
localization sequence and would therefore not be
expected to be targeted to the nucleus. CaMK-II need
not enter the nucleus to function in regulating cell
growth control; it could act through the modification
of a cytoplasmic member of the growth signaling
cascade, as suggested by its kinetics of activation
w x26 .
Domain IV, rich in basic amino acids is found in
g , g , g , b X and b . Neither this domain norB G H e e
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domain V have strong tissue-specificity, being found
in both neuronal and non-neuronal isozymes. Domain
 .V is rich in proline 20–27% and is found in half of
all CaMK-II’s. Of the tumor cell CaMK-II’s, b X, be e
and g CaMK-II contain insert V. This domain wasB
implied by comparing the sequence of the g , gD G
and g CaMK-II isozymes. This suggests gene orH
species-specific exon differences since domains IV
and V are encoded as a single exon in rodent b
w xCaMK-II 32 .
Domain VI is found in all g isozymes including
g , g , g and g Within domain VI, Thr 382 isB C G H
w xrapidly autophosphorylated in b CaMK-II 9,30 , but
the result of its phosphorylation is not known. Of
domains IV, V and VI, each tumor cell CaMK-II
contains between 1 and 3 of these domains, except
for d , which contains none.C
Domain VII is found in every CaMK-II; its length
and three quarters of its amino acids are absolutely
invariant. This domain has a net charge of y4 to y5
and contains between 29 and 41% serine or threonine
residues. It is believed to be at the beginning of the
‘association domain’ and is therefore analogous to
domain II, serving as a conserved tether between the
variable and association domains.
Domains VIII and IX are specific to the g CaMK-II
gene. Domain VIII is a 10 amino acid domain spe-
cific to g , g and g while domain IX is a 28D E F
amino acid insert specific to g , g , g and g .D B F G
Among the tumor cell CaMK-II’s described in this
study, domain IX was found in g CaMKII, but notG
in g CaMK-II. Unlike other domains, VIII and IXH
have only been found in nonneuronal g isozymes and
therefore appear to be g gene-specific. The absence
of domain VIII from both g and g CaMK-IIG H
defines another potential exon boundary not previ-
ously realized.
Domain X is a b CaMK-II-specific proline-rich
domain described only in CaMK-II b from the rat3
w xpancreas 33 . This domain was not identified, how-
w xever, in the genomic mouse CaMK-II sequence 32 .
Interestingly, this domain conforms to SH3-binding
sequences, and may therefore be targeted directly to
w xthe growth factor machinery 33 . These domains
could also target isozymes to subcellular sites or
substrates or influence the oligomeric nature of
CaMK-II.
There are several additional mammalian d CaMK-
II isozymes whose variability is additionally con-
ferred at the distal C-terminus, where the last 21
w xamino acids are either inserted or deleted 36 . These
additions are specific to d CaMK-II’s. Fig. 6 reveals
that CaMK-II d , like CaMK-II a , contains only 2C
of the 7 possible variable domains in the variable
region.
In summary, the results presented here suggest that
at some point in neuronal tumorigenesis, the a
CaMK-II gene is turned off and the splicing signals
amongst the other three CaMK-II genes are similarly
changed; i.e., all new variants are truncated with
similar domain omissions. These results also suggest
that the opposite change in CaMK-II splicing accom-
panies differentiation since undifferentiated embry-
onic fibroblasts have a pattern distinct from adult
differentiated neuronal tissue and much more like
that of tumor cells.
Transformed cells have previously been shown to
undergo alterations in their dependence on Ca2q, in
their level of CaM and in CaM binding proteins
w x3,49–54 . This report now shows that they also
undergo changes in the expression pattern of CaMK-
 .II. Although it is not known which isozyme s may
regulate cell growth in human tumor cells, the inap-
propriate expression of CaMKII variants in tumor
cells may contribute to the malignant phenotype.
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